济川药业子公司与泽德曼签署独占性商业化权益协议

Core Viewpoint - Jichuan Pharmaceutical has signed an exclusive commercialization rights agreement with Zedeman, allowing Jichuan to exclusively commercialize Zedeman's product, Zeli Me Benweimode Cream, in mainland China for a total payment of up to 190 million yuan (including tax) [1] Group 1 - Jichuan Pharmaceutical's subsidiary, Jichuan Pharmaceutical Group Co., Ltd., will be responsible for the commercialization of Zedeman's product in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - The total payment for the agreement, including upfront and milestone payments, will not exceed 190 million yuan [1] - This transaction is expected to enhance the product line of Jichuan Pharmaceutical, contributing to the sustainable development of the company's business and aligning with its strategic goals [1]